GlassScriptPhysician profile
Abigail Mowry Tremelling
NPI 1740624857
$2,002.66
in general payments reported to CMS, 2019-2025
19 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2021: $24.17 · 2023: $404 · 2024: $858 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Travel and Lodging: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.01 |
| Travel and Lodging | $465.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $790.69 | 2024-2025 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Endomagnetics LTD | $194.69 | 2023 | Magseed, Magtrace |
| Medtronic USA, INC. | $165.23 | 2019 | |
| Stryker Corporation | $148.85 | 2019 | |
| Merit Medical Systems INC | $122.65 | 2023 | Savi Scout |
| Carl Zeiss Meditec, INC. | $99.04 | 2019 | |
| Molli Surgical (US) INC | $86.53 | 2023 | |
| Hologic Sales and Service, LLC | $74.32 | 2024-2025 | Magseed, Localizer, Trident Specimen Radiography System |
| Merck Sharp & Dohme LLC | $73.61 | 2024-2025 | Lynparza, Keytruda |
| Lilly USA, LLC | $37.68 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $36.06 | 2025 | |
| Janssen Biotech, INC. | $28.05 | 2025 | Tecvayli, Darzalex, Rybrevant |
| Hologic INC | $24.17 | 2021 | |
| Pharmaessentia USA Corporation | $22.88 | 2025 | Besremi |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.81 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.30 | 2025 | Fruzaqla |
| Sun Pharmaceutical Industries INC. | $18.69 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Tremelling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.